Lundbeck announced new data from an oral abstract for VYEPTI® (eptinezumab-jjmr), along with three poster presentations, are being presented at the 2022 Annual Scientific Meeting of the American Academy of Neurology (AAN), which is being held in person from April 2-7 and virtually from April 24-26. The findings are part of a post hoc analysis of one of two pivotal trials, PROMISE 2 (NCT02974153), a randomized, double-blind study that evaluated VYEPTI for the preventive treatment of chronic migraine. Results showed that a higher percentage of people with chronic migraine who experienced a reduction to 4 or fewer monthly headache days (MHDs) achieved improved health outcomes (headache impairment as measured by the 6-item Headache Impact Test (HIT-6) and improvements in Patient Global Impression of Change (PGIC)) and required less acute medication versus people with chronic migraine who experienced higher MHDs (5-9, 10-14, =15).

Study participants received VYEPTI 100 mg, 300 mg, or placebo; all treatment arms were pooled for the analysis. The study (SC1.002) combined available HIT-6 and PGIC data, along with days of acute medication use, and organized that data based on the number of MHDs (=4, 5-9, 10-14, =15) experienced during 4-week assessment periods, called patient-months. In the abstract, 67.6% of the months where people with chronic migraine experienced =4 MHDs were associated with “little to none” or “some” headache impairment (as measured by the HIT-6 total score), compared to 47.6%, 29.9%, and 13.9% of months where people with chronic migraine experienced 5-9, 10-14, and =15 MHDs, respectively.

In addition, 85.8% of these months (where people with chronic migraine experienced =4 MHDs) were associated with PGIC reports of feeling “very much” or “much” improved, vs. 69.9%, 49.6%, and 21.5% of months where people with chronic migraine experienced 5-9, 10-14, and =15 MHDs, respectively.1 The use of acute medication for fewer than 10 days a month occurred less often in months with =4 MHDs (1.9%), compared to months with 5-9 (5.0%), 10-14 (49.6%), and =15 (74.1%) MHDs.